Fate Therapeutics (FATE) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Fate Therapeutics (FATE) over the last 6 years, with Q3 2025 value amounting to -$0.27.
- Fate Therapeutics' EPS (Weighted Average and Diluted) rose 3250.0% to -$0.27 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.33, marking a year-over-year increase of 1939.39%. This contributed to the annual value of -$1.7 for FY2024, which is 351.01% down from last year.
- Latest data reveals that Fate Therapeutics reported EPS (Weighted Average and Diluted) of -$0.27 as of Q3 2025, which was up 3250.0% from -$0.29 recorded in Q2 2025.
- Over the past 5 years, Fate Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.19 during Q1 2023, and registered a low of -$0.86 during Q3 2022.
- For the 5-year period, Fate Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.49, with its median value being -$0.46 (2023).
- Per our database at Business Quant, Fate Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 7205.88% in 2023 and then plummeted by 14736.84% in 2024.
- Fate Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.72 in 2021, then grew by 19.44% to -$0.58 in 2022, then grew by 22.41% to -$0.45 in 2023, then fell by 13.13% to -$0.51 in 2024, then surged by 46.96% to -$0.27 in 2025.
- Its last three reported values are -$0.27 in Q3 2025, -$0.29 for Q2 2025, and -$0.32 during Q1 2025.